ÂÜÀòÂÒÂ×

Jim Millen is the CEO of Physiomics plc, a Manchester, UK biotech spin-out conducting research into the use of therapeutic proteins for the treatment of human disease. Prior to this, they were the Director of Oval Medical Technologies, a non-executive board member with special focus on transactions. Jim was also a Partner at Treehill Partners, where they provided independent advice and interim management in M&A, licensing, commercial strategy and capital raising in the lifesciences and healthcare sectors. Jim Millen has over 7 years of experience as Head of Commercial Strategy and Market Access for Neurosciences at Allergan. In this role, they were responsible for developing and implementing commercial/pricing strategies to maximise the value of the neurosciences franchise across the Europe, Middle East and Africa region.

Jim Millen has an MBA from INSEAD, an Advanced Diploma in Management Accounting from CIMA, and an MBBS from the University of London. Jim also has a BA in Medical Science from the University of Cambridge. Jim is certified by the General Medical Council in Full registration without license to practice.

Christophe Chassagnole - COO, Anthony Clayden - Head of Finance, and Frances Brightman - Project Leader report to Jim Millen.